Effect of Calcimimetic Agent, KRN568, on Gastrin Secretion in Healthy Subjects

KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extrac...

Full description

Saved in:
Bibliographic Details
Published in:ENDOCRINE JOURNAL Vol. 47; no. 5; pp. 517 - 523
Main Authors: IGARASHI, TETSUYA, OGATA, ETSURO, MARUYAMA, KAZUNOBU, FUKUDA, TSUYOSHI, AZUMA, JUNICHI
Format: Journal Article
Language:English
Published: Japan The Japan Endocrine Society 2000
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level. However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90.8 and non-fasting 83.8ng/ml) compared to the other 5 individuals (Cmax 6.5±2.2 and 7.4±1.6ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34±6 to 63±3pg/ml) after oral administration of 400mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound.
AbstractList KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level. However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently carried out in Japan. Single doses of KRN568, ranging from 25 mg to 400 mg, were orally administered to 6 healthy male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90.8 and non-fasting 83.8 ng/ml) compared to the other 5 individuals (Cmax 6.5 plus or minus 2.2 and 7.4 plus or minus 1.6 ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125 pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34 plus or minus 6 to 63 plus or minus 3 pg/ml) after oral administration of 400 mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound.
KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level. However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently carried out in Japan. Single doses of KRN568, ranging from 25 mg to 400 mg, were orally administered to 6 healthy male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90.8 and non-fasting 83.8 ng/ml) compared to the other 5 individuals (Cmax 6.5 +/- 2.2 and 7.4+/- 1.6 ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125 pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34 +/- 6 to 63 +/- 3 pg/ml) after oral administration of 400 mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound.
KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level. However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90.8 and non-fasting 83.8ng/ml) compared to the other 5 individuals (Cmax 6.5±2.2 and 7.4±1.6ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34±6 to 63±3pg/ml) after oral administration of 400mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound.
KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has demonstrated that CaRs are expressed on cultured human antral gastrin cells and that gastrin secretion is stimulated by an increase in extracellular calcium level . However, the effect of KRN568 on serum gastrin levels has yet to be clinically assessed. We therefore studied the effect of this calcimimetic on gastrin secretion in healthy subjects enrolled in the phase 1 study for KRN568 currently carried out in Japan. Single doses of KRN568, ranging from 25 mg to 400 mg, were orally administered to 6 healthy male volunteers at fasting and after meal. One subject proved to be a poor metabolizer (PM) for this compound and showed more than 10-fold high concentrations of plasma KRN568 (fasting Cmax 90. 8 and non-fasting 83. 8 ng/ml) compared to the other 5 individuals (Cmax 6. 5±2. 2 and 7. 4±1. 6 ng/ml, respectively). Plasma gastrin levels showed mild but apparent increase (from 30 to 125 pg/ml) in this particular subject, while there were no significant increases in the other five people (from 34±6 to 63±3 pg/ml) after oral administration of 400 mg KRN568 at fasting. In the PM, administration of KRN568 resulted in extraordinarily high serum drug levels associated with transient increase of gastrin levels. This observation suggested that calcium-induced stimulation of gastrin secretion in human was mediated by a mechanism involving CaR. Potential side effects related to the increased gastrin secretion may be warranted in the practical use of this compound.
Author AZUMA, JUNICHI
IGARASHI, TETSUYA
MARUYAMA, KAZUNOBU
FUKUDA, TSUYOSHI
OGATA, ETSURO
Author_xml – sequence: 1
  fullname: IGARASHI, TETSUYA
  organization: Department of Internal Medicine, University of Tokyo Branch Hospital, University of Tokyo
– sequence: 2
  fullname: OGATA, ETSURO
  organization: Cancer Institute Hospital
– sequence: 3
  fullname: MARUYAMA, KAZUNOBU
  organization: Osaka Pharmacology Research Clinic
– sequence: 4
  fullname: FUKUDA, TSUYOSHI
  organization: Clinical Evaluation of Medicines and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University
– sequence: 5
  fullname: AZUMA, JUNICHI
  organization: Clinical Evaluation of Medicines and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/11200930$$D View this record in MEDLINE/PubMed
BookMark eNqFkUFP3DAQRq0KVBbKtccqp57IYnvs2DmiFSxVEZVKOVuO14ZEiQN2cuDfM5ClPfbikT3Pz6PPx-QgjtET8pXRNZNUnfu4G13q1kKtJVOfyIqB0KWQgh6QFa2ZLnUt6yNynHNHKYAU8JkcMcYprYGuyO1lCN5NxRiKje1dO7SDn1pXXDz4OJ0VP3_fykqfFWMstjZPqY3FnXcJETzBzbW3_fT4UtzNTYea_IUcBttnf7qvJ-T-6vLP5rq8-bX9sbm4KV2l5VRqGyRvODR1DRXjsgYRtFA8aKmAMS0b5naBQuNBYU9rUUkquFWiwoYIcEK-L96nND7PPk9maLPzfW-jH-dsFJcgAcR_QaaZrBVnCK4X0KUx5-SDeUrtYNOLYdS8RW32URuhDEaNF77tzXMz-N0_fJ8tAlcLgN3W2X6MfRu96cY5RczGuOfqXWmQp4ZSoajEwg1FPS4cGHBOKxRtF1GXJ_vg_75kE_5U7z8GYxjm-3DL8ib5INyjTYjBK_UOqS0
CitedBy_id crossref_primary_10_1007_s00198_008_0637_8
crossref_primary_10_1016_j_ceca_2003_10_020
crossref_primary_10_1111_bph_12420
crossref_primary_10_1016_j_pharmthera_2005_06_019
crossref_primary_10_1051_medsci_20042011973
crossref_primary_10_1359_JBMR_051210
crossref_primary_10_1007_s00467_009_1153_6
crossref_primary_10_1016_j_bone_2004_03_021
crossref_primary_10_1053_gast_2001_23246
ContentType Journal Article
Copyright The Japan Endocrine Society
Copyright_xml – notice: The Japan Endocrine Society
CorporateAuthor University of Tokyo Branch Hospital
Department of Internal Medicine
University of Tokyo
Cancer Institute Hospital
Clinical Evaluation of Medicines and Therapeutics
Osaka University
Graduate School of Pharmaceutical Sciences
Osaka Pharmacology Research Clinic
CorporateAuthor_xml – name: University of Tokyo Branch Hospital
– name: University of Tokyo
– name: Osaka University
– name: Cancer Institute Hospital
– name: Osaka Pharmacology Research Clinic
– name: Graduate School of Pharmaceutical Sciences
– name: Department of Internal Medicine
– name: Clinical Evaluation of Medicines and Therapeutics
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7X8
DOI 10.1507/endocrj.47.517
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Calcium & Calcified Tissue Abstracts
MEDLINE - Academic
DatabaseTitleList Calcium & Calcified Tissue Abstracts
MEDLINE


Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1348-4540
EndPage 523
ExternalDocumentID 10_1507_endocrj_47_517
11200930
cq6endoc_2000_004705_002_0517_0523132206
article_endocrj1993_47_5_47_5_517_article_char_en
Genre Clinical Trial
Journal Article
GroupedDBID ---
.55
.GJ
29G
2WC
3O-
53G
5GY
5RE
AAEJM
AAUGY
ACPRK
ACRZS
ADBBV
AENEX
AJJEV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKOMP
CS3
DIK
DU5
E3Z
EBD
EBS
EJD
EMOBN
F5P
JMI
JSF
JSH
KQ8
MOJWN
M~E
OK1
P2P
RJT
RNS
RZJ
SV3
TKC
TR2
X7M
XSB
ZGI
ZXP
AFPKN
GROUPED_DOAJ
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7QP
7X8
ID FETCH-LOGICAL-c685t-8af52b23b9936125934f8472f85731185b1cdf03be3793488465042a7461cd4f3
ISSN 0918-8959
IngestDate Sat Aug 17 00:49:52 EDT 2024
Fri Aug 16 08:02:00 EDT 2024
Thu Nov 21 21:00:54 EST 2024
Sat Sep 28 08:40:21 EDT 2024
Fri Nov 08 06:50:52 EST 2024
Thu Aug 17 20:29:52 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c685t-8af52b23b9936125934f8472f85731185b1cdf03be3793488465042a7461cd4f3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/endocrj1993/47/5/47_5_517/_article/-char/en
PMID 11200930
PQID 18159721
PQPubID 23462
PageCount 7
ParticipantIDs proquest_miscellaneous_72535334
proquest_miscellaneous_18159721
crossref_primary_10_1507_endocrj_47_517
pubmed_primary_11200930
medicalonline_journals_cq6endoc_2000_004705_002_0517_0523132206
jstage_primary_article_endocrj1993_47_5_47_5_517_article_char_en
PublicationCentury 2000
PublicationDate 2000-00-00
PublicationDateYYYYMMDD 2000-01-01
PublicationDate_xml – year: 2000
  text: 2000-00-00
PublicationDecade 2000
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle ENDOCRINE JOURNAL
PublicationTitleAlternate Endocr J
PublicationYear 2000
Publisher The Japan Endocrine Society
Publisher_xml – name: The Japan Endocrine Society
References 2). Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, Del Mar EG, Balandrin MF (1998) Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA 95: 4040-4045.
5). Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR, Gulbrandsen AK (1995) Detection of poor metabolizer-associated CYP2D6 (D) gene deletion allele by long-PCR technology. Pharmacogenetics 5: 215-223.
11). Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ, Spiegel AM, Marx SJ (1998) Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J Clin Endocrinol Metab 83: 1083-1088.
6). de Morais SMF, Wilkinson GR, Blaisdell GRJ, Nakamura K, Meyer UA, Goldstein JA (1994) Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 46: 594-598.
8). Brown EM, Pollak M, Hebert SC (1998) The extracellular calcium-sensing receptor: its role in health and disease. Annu Rev Med 49: 15-29.
18). Hoensch HP, Hutzel H, Kirch W, Ohnhaus EE (1985) Isolation of human hepatic microsomes and their inhibition by cimetidine and ranitidine. Eur J Clin Pharmacol 29: 199-206.
4). Fukuda T, Yamamoto I, Nishida Y, Zhou Q, Ohno M, Takada K, Azuma J (1999) Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47: 450-453.
7). Zhou Q, Yamamoto I, Fukuda T, Ohno M, Sumida A, Azuma J (1999) CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. Eur J Clin Pharmacol 55: 43-47.
17). Sachse C, Brockmoller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60: 284-289.
9). Cheng I, Qureshi I, Chattopadhyay N, Qureshi A, Butters RR, Hall AE, Cima RR, Rogers KV, Hebert SC, Geibel JP, Brown EM, Soybel DI (1999) Expression of an extracellular calcium-sensing receptor in rat stomach. Gastroenterology 116: 118-126.
1). Bloom SR, Polak JM (1995) The endocrine gastrointestinal tract: Pathophysiology. In Principles and Practice of Endocrinology and Metabolism. Becker KL (ed) JB Lippincott Co., Philadelphia, 1499-1512.
14). Lamers CG, Van Tongeren JH (1977) Comparative study of the value of the calcium, secretin, and meal stimulated increase in serum gastrin to the diagnosis of the Zollinger-Ellison syndrome. Gut 18: 128-135.
16). Nishida Y, Fukuda T, Yamamoto I, Azuma J (2000) The CYP2D6 genotypes in a Japanese population; low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10. Pharmacogenetics (in press).
19). Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol 46: 452-459.
12). Silverberg SJ, Bone HG, 3rd, Marriott TB, Locker FG, Thys-Jacobs S, Dziem G, Kaatz S, Sanguinetti EL, Bilezikian JP (1997) Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism. N Engl J Med 337: 1506-1510.
3). Ray JM, Squires PE, Curtis SB, Meloche MR,Buchan AM (1997) Expression of the calcium-sensing receptor on human antral gastrin cells in culture. J Clin Invest 99: 2328-2333.
10). Nemeth EF, Fox J (1999) Calcimimetic compounds: a direct approach to controlling plasma levels of parathyroid hormone in hyperparathyroidism. Trends in Endocrinology and Metabolism 10: 66-71.
15). Coburn JW, Maung HM (2000) Calcimimetic agents and the calcium-sensing receptor. Curr Opin Nephrol Hypertens 9: 123-132.
13). Antonsen JE, Sherrard DJ, Andress DL (1998) A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int 53: 223-227.
References_xml
SSID ssj0033543
ssib022572652
ssib002822051
ssib000750009
Score 1.6527995
Snippet KRN568 is a calcimimetic compound which acts on the calcium sensing receptors (CaR) on the parathyroid gland to suppress secretion of PTH. A recent report has...
SourceID proquest
crossref
pubmed
medicalonline
jstage
SourceType Aggregation Database
Index Database
Publisher
StartPage 517
SubjectTerms Administration, Oral
Adult
Aniline Compounds - pharmacokinetics
Aniline Compounds - pharmacology
Calcimimetics
Calcium - agonists
Calcium-sensing receptor
Cytochrome P-450 Enzyme System - genetics
Gastrin
Gastrins - blood
Gastrins - metabolism
Genotype
Humans
Male
Phenethylamines
Polymerase Chain Reaction
Polymorphism, Restriction Fragment Length
Propylamines
Title Effect of Calcimimetic Agent, KRN568, on Gastrin Secretion in Healthy Subjects
URI https://www.jstage.jst.go.jp/article/endocrj1993/47/5/47_5_517/_article/-char/en
http://mol.medicalonline.jp/en/journal/download?GoodsID=cq6endoc/2000/004705/002&name=0517-0523e
https://www.ncbi.nlm.nih.gov/pubmed/11200930
https://search.proquest.com/docview/18159721
https://search.proquest.com/docview/72535334
Volume 47
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Endocrine Journal, 2000, Vol.47(5), pp.517-523
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELe6gRASQnyvfPoBiYcuWxp_xH0CxFoNsXUSdNLeLOer2lhTaJaH_ffc2U7aCE3AAy9pmtpWcverc3e--5mQtwCaXGaKB7m0pNpSBGooM3BVWIbvJyPtXgSH3-LpmToY83Gv19BArK_9V03DNdA1Vs7-g7bbQeECnIPO4Qhah-Nf6d3TEWO2uLlMzxfni9xysmIJlf1Xf50KqfAM9D43uG1HOajQeGzSHl1p5PWgqhMM0lSd4H2ZLVMsGBxs3gxCa25WuC9TJ-_6ZG6ccdqWOxybVX1tFqYTYJ3U3-vMrHs2QYhwM444VIEaeVpvP6U6Ek0PHbExPwpXqOlftcKVGv82iwubuJHbJ7rY4_Fe222TLnt6oienR0d6Nj6bbZFbEcw0uIXFwecvzauYMeHSJpt79KydMP5-d_SOVXL7AgxzZFy4t3CLZY605GYfxNoiswfkvnci6Een_Yekl5ePyJ1jnybxmEwdCOiyoJsgoBYEu9RBYJcuS-oBQFsAUPjiAUAbADwhp5Px7NNh4DfOCFKpxFWgTCGiJGIJGJ9owY4YL8AKiQolYgYepUiGaVaELMkZCA2mcA52Oo9MzCX8wAv2lGyXyzLfITROR0oa8Mt5mHORF6pI0wxcYAmyTdJI9sm7RnD6h-NH0ehXgoi1F7HmsQYR98kHJ9e2nf-PNO0wldS2dQfo0rbACkRo1ifvOxrRHuqVTn9KOwruqop8tzwOBXxEGinoNC59YNQlhNt90-hQwzyKi2OmzJd1pcHSFchkdXOLOBIMC9f75JlT_vqBh7jGyMLnf-z7gtx1XA4Yw3tJtq9Wdf6KbFVZ_doi9xfiG6Cr
link.rule.ids 315,782,786,4028,27932,27933,27934
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+calcimimetic+agent%2C+KRN568%2C+on+gastrin+secretion+in+healthy+subjects&rft.jtitle=Endocrine+journal&rft.au=Igarashi%2C+T&rft.au=Ogata%2C+E&rft.au=Maruyama%2C+K&rft.au=Fukuda%2C+T&rft.date=2000&rft.issn=0918-8959&rft.volume=47&rft.issue=5&rft.spage=517&rft.epage=523&rft_id=info:doi/10.1507%2Fendocrj.47.517&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-8959&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-8959&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-8959&client=summon